National Cancer Institute; Notice of Closed Meeting, 8598 [06-1467]

Download as PDF 8598 Federal Register / Vol. 71, No. 33 / Friday, February 17, 2006 / Notices Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/ 496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications. ADDRESSES: sroberts on PROD1PC70 with NOTICES Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use Barry R. O’Keefe et al. (NCI) U.S. Provisional Application No. 60/ 741,403 filed 01 Dec 2005 (HHS Reference No. E–025–2006/0–US–01). Licensing Contact: Sally H. Hu, Ph.D., M.B.A.; 301/435–5606; hus@mail.nih.gov. The invention provides for a composition of an anti-viral polypeptide, Griffithsin, glycosylationresistant Griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, antibodies and methods of production and use. More specifically, Griffithsin inhibits viral binding, fusion and entry into the host cells by binding to viral envelope gp120. Thus, subject invention can be developed as an inhibitor therapeutically or prophylactically against retroviral infections including HIV–1 and HIV–2 as well as FIV, SIV, MLV, BLV, equine infectious virus, avian sarcoma viruses, and HTLV. Subject invention also can be developed as an inhibitor against non-retroviruses infectious such as influenza virus, including H5N1, SARS, Hepatitis C, and Ebola, measles, varicella, human herpes viruses and others. In addition, Griffithsin can be used in combination with other anti-viral agents to treat patients who have drug-resistant virus. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. Discovery of Tropolone Inhibitors of HIV–1 Integrase That Can Be Used for the Treatment of Retroviral Infection, Including AIDS Yves Pommier, Christophe Marchand, Elena Semenova, Allison Johnson (NCI). U.S. Provisional Application No. 60/ 741,769 filed 01 Dec 2005 (HHS Reference No. E–308–2005/0–US–01). Licensing Contact: Sally H. Hu, Ph.D., M.B.A.; 301/435–5606; hus@mail.nih.gov. This invention provides pharmaceutical compositions VerDate Aug<31>2005 18:51 Feb 16, 2006 Jkt 208001 comprising one or more HIV–1 integrase inhibitor compounds, as well as methods for treatment or prevention of HIV infection. These compounds are alpha-hydroxytropolone or its salt, solvate or hydrate, and they have been shown to inhibit the integrase by interfering with the enzyme catalytic site by chelating magnesium ions, and have been shown to inhibit the strand transfer reaction. Integrase is an important target for AIDS therapy since it is critical for viral replication, and does not have cellular counterparts, which can potentially reduce toxic side effects. Thus, the compounds of this invention can be developed as novel anti-viral agents that can be used in combinational therapy, especially since they might be less toxic than other antiviral agents. In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors. Dated: February 10, 2006. Steven M. Ferguson, Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. E6–2357 Filed 2–16–06; 8:45 am] Contact Person: Timothy C. Meeker, MD, Ph.D., Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8088, Bethesda, MD 20892. (301) 594– 1279, meekert@mail.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: February 10, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–1467 Filed 2–16–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health BILLING CODE 4140–01–P National Cancer Institute; Notice of Closed Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Institutes of Health National Cancer Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Initial Review Group, Subcommittee H—Clinical Groups. Date: March 6–8, 2006. Time: 6 p.m. to 9:30 a.m. Agenda: To review and evaluate grant applications. Place: Providence Biltmore, 11 Dorrance Street, Providence, RI 02903. PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 Name of Committee: National Cancer Institute Special Emphasis Panel; SBIR Topic 217, ‘‘Nanoparticle Biosensors for Recognition of Exposure and Risk Analysis in Cancer’’. Date: March 16, 2006. Time: 12 p.m. to 4 p.m. Agenda: To review and evaluate contract applications. Place: National Institutes of Health, 6116 Executive Boulevard, Rockville, MD 20852. (Telephone Conference Call). Contact Person: C. Michael Kerwin PhD, MPH, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of E:\FR\FM\17FEN1.SGM 17FEN1

Agencies

[Federal Register Volume 71, Number 33 (Friday, February 17, 2006)]
[Notices]
[Page 8598]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-1467]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Initial Review 
Group, Subcommittee H--Clinical Groups.
    Date: March 6-8, 2006.
    Time: 6 p.m. to 9:30 a.m.
    Agenda: To review and evaluate grant applications.
    Place: Providence Biltmore, 11 Dorrance Street, Providence, RI 
02903.
    Contact Person: Timothy C. Meeker, MD, Ph.D., Scientific Review 
Administrator, Resources and Training Review Branch, Division of 
Extramural Activities, National Cancer Institute, 6116 Executive 
Boulevard, Room 8088, Bethesda, MD 20892. (301) 594-1279, 
meekert@mail.nih.gov.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: February 10, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 06-1467 Filed 2-16-06; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.